0.00%
-1.04%
300.84%
169.12%
176.16%
100.00%
-38.11%
AI Spotlight on PSTX
Company Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers.
In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma.Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC.Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates.
It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited.The company was incorporated in 2014 and is headquartered in San Diego, California.
Market Data
| Last Price | 9.5 |
| Change Percentage | 0.00% |
| Open | 9.58 |
| Previous Close | 9.5 |
| Market Cap ( Millions) | 926 |
| Volume | 21344052 |
| Year High | 9.67 |
| Year Low | 1.87 |
| M A 50 | 6.66 |
| M A 200 | 3.82 |
Financial Ratios
| FCF Yield | -1.85% |
| Dividend Yield | 0.00% |
| ROE | -70.65% |
| Debt / Equity | 94.86% |
| Net Debt / EBIDTA | -72.34% |
| Price To Book | 10.58 |
| Price Earnings Ratio | -15.54 |
| Price To FCF | -54.07 |
| Price To sales | 6.14 |
| EV / EBITDA | -20.78 |
News
- Jan -08 - Roche set to finalise $1.5bn Poseida Therapeutics takeover
- Jan -08 - Roche to complete acquisition of U.S. biopharma company Poseida
- Dec -09 - Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
- Nov -28 - Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?
- Nov -27 - POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX
- Nov -27 - Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet
- Nov -27 - Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?
- Nov -27 - SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc. - PSTX
- Nov -26 - Poseida shares triple on Tuesday, boosted by Roche collaboration
- Nov -26 - Why This Gene-Therapy Company's Stock Is Rising 228%
- Nov -26 - Shareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
- Nov -26 - Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
- Nov -26 - PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders
- Nov -26 - Roche to acquire US-based Poseida Therapeutics
- Nov -26 - Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
- Nov -14 - Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
- Nov -11 - Poseida Therapeutics to Present at Two Upcoming Investor Conferences
- Nov -07 - Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates
- Nov -07 - Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024
- Nov -05 - Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Cell and Gene Therapies
Expected Growth : 14.05 %
What the company do ?
Poseida Therapeutics, Inc. develops cell and gene therapies, including CAR-T cell therapies, to treat various cancers and genetic disorders, using its proprietary piggyBac DNA modification and Cas-CLOVER gene editing technologies.
Why we expect these perspectives ?
Poseida Therapeutics' Cell and Gene Therapies segment growth is driven by increasing adoption of CAR-T cell therapies, strong pipeline of gene editing programs, and partnerships with leading pharmaceutical companies. Additionally, growing demand for targeted cancer treatments, advancements in gene editing technologies, and expanding indications for existing products contribute to the 14.05% growth.
Poseida Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| BCMA Targeted CAR-T Cell Therapy | Autologous CAR-T cell therapy targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma |
| PSMA Targeted CAR-T Cell Therapy | Allogenic CAR-T cell therapy targeting prostate-specific membrane antigen (PSMA) for the treatment of metastatic castration-resistant prostate cancer |
| PSCA Targeted CAR-T Cell Therapy | Autologous CAR-T cell therapy targeting prostate stem cell antigen (PSCA) for the treatment of pancreatic cancer |
| BCMA Allogenic CAR-T Cell Therapy | Allogenic CAR-T cell therapy targeting BCMA for the treatment of relapsed/refractory multiple myeloma |
| P-PSMA-101 (PSMA-Targeted Autologous CAR-T Cell Therapy) | Autologous CAR-T cell therapy targeting PSMA for the treatment of metastatic castration-resistant prostate cancer |
Poseida Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
Poseida Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative gene therapies and treatments for similar diseases.
Bargaining Power Of Customers
Poseida Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the high demand for innovative gene therapies.
Bargaining Power Of Suppliers
Poseida Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment, but also due to the specialized nature of some of the components required for gene therapy production.
Threat Of New Entrants
Poseida Therapeutics, Inc. faces a high threat of new entrants due to the growing interest in gene therapy and the increasing number of biotech startups and pharmaceutical companies investing in gene therapy research and development.
Intensity Of Rivalry
Poseida Therapeutics, Inc. operates in a highly competitive industry with several established players and a growing number of new entrants, leading to a high intensity of rivalry in the gene therapy market.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 38.36% |
| Debt Cost | 3.95% |
| Equity Weight | 61.64% |
| Equity Cost | 6.22% |
| WACC | 5.35% |
| Leverage | 62.24% |
Poseida Therapeutics, Inc. : Quality Control
Poseida Therapeutics, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OCUL | Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company … |
| EYPT | EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, … |
| ABUS | Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of … |
| BCRX | BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the … |
| GTHX | G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ocular Therapeutix
A-Score
1-Year Total Return ->
🥈
Arbutus Biopharma
A-Score
1-Year Total Return ->
🥉
BioCryst Pharmaceuticals
A-Score
1-Year Total Return ->
4
Poseida Therapeutics
A-Score
1-Year Total Return ->
5
G1 Therapeutics
A-Score
1-Year Total Return ->
6
